WXSH0102

WXSH0102 is an investigational small molecule drug developed by Cisen Pharmaceutical for the treatment of vulvovaginal candidiasis (VVC), a fungal infection of the vulva and vagina caused primarily by Candida species. The drug is currently in Phase 2 clinical trials, where it is being evaluated for its efficacy, safety, and pharmacokinetics in adult patients with VVC. The mechanism of action has not been explicitly disclosed in public sources; however, based on its development focus and trial design, it is presumed to act as an antifungal agent targeting pathogenic fungi responsible for VVC[1][3][5]. Clinical studies have also assessed its safety and tolerability in healthy adults[1].